CVS vs. HQY: Which Stock Is the Better Value Option?

Zacks Research identifies CVS Health (CVS) as the superior value investment option over HealthEquity (HQY) within the Medical Services sector. CVS holds a Zacks Rank #2 (Buy) and a Value grade of 'A', contrasting with HQY's Zacks Rank #3 (Hold) and 'C' grade. This preference is driven by CVS's more favorable valuation metrics, including a forward P/E of 11.31 versus HQY's 23.93, a PEG ratio of 0.79 compared to HQY's 1.15, and a P/B of 1.17 against HQY's 3.64, positioning CVS as the better value opportunity for investors.

Analysis

A comparative fundamental analysis within the Medical Services sector positions CVS Health (CVS) as a superior value opportunity relative to HealthEquity (HQY). This assessment is primarily driven by CVS's stronger quantitative ratings, including a Zacks Rank of #2 (Buy) versus HQY's #3 (Hold), which signals more favorable earnings estimate revisions and an improving outlook for CVS. On key valuation metrics, CVS appears significantly undervalued compared to its peer. It trades at a forward P/E ratio of 11.31, less than half of HQY's 23.93. Furthermore, CVS's PEG ratio of 0.79 is below the 1.0 threshold often used to identify stocks that may be undervalued relative to their expected earnings growth, contrasting sharply with HQY's PEG of 1.15. The disparity is also evident in book value, with CVS's P/B ratio at 1.17 compared to HQY's 3.64. These combined factors contribute to CVS earning a top-tier 'A' grade for Value in the Zacks Style Scores system, while HQY receives a 'C', reinforcing the conclusion that CVS presents a more compelling case for value-focused investors.

Key Decisions for Investors

• Value-oriented investors should consider CVS Health a compelling opportunity, given its attractive valuation multiples including a sub-1.0 PEG ratio and positive earnings revision trends.
• Investors holding or evaluating HealthEquity should be aware of its premium valuation, as its forward P/E and PEG ratios suggest growth expectations are already priced in, posing a potential risk if growth moderates.
• For portfolios with exposure to the Medical Services sector, re-weighting capital from HQY to CVS could be a prudent move to capitalize on the significant valuation gap between the two companies.